[
  {
    "ts": null,
    "headline": "From Cobenfy to Emraclidine: the muscarinic path to safer antipsychotics",
    "summary": "Drugs such as Cobenfy could reshape the antipsychotic market, providing a more nuanced range of patient options.",
    "url": "https://finnhub.io/api/news?id=7afc480e863cd65a2ad1caa4e680442b8771836c8f5f96685efcb176f23754cc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733246309,
      "headline": "From Cobenfy to Emraclidine: the muscarinic path to safer antipsychotics",
      "id": 131758062,
      "image": "https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/24/2024/12/shutterstock_1337875463.jpg",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Drugs such as Cobenfy could reshape the antipsychotic market, providing a more nuanced range of patient options.",
      "url": "https://finnhub.io/api/news?id=7afc480e863cd65a2ad1caa4e680442b8771836c8f5f96685efcb176f23754cc"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. stock outperforms competitors despite losses on the day",
    "summary": "AbbVie Inc. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=c5bbb05ce0771bdf5fc24129e174179567d55355bdc3e04aad7a838610028f47",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733243640,
      "headline": "AbbVie Inc. stock outperforms competitors despite losses on the day",
      "id": 131775419,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=c5bbb05ce0771bdf5fc24129e174179567d55355bdc3e04aad7a838610028f47"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. (ABBV) Citi's 2024 Global Healthcare Conference (Transcript)",
    "summary": "AbbVie Inc. (NYSE:ABBV) Citi's 2024 Global Healthcare Conference Call December 3, 2024 10:15 AM ETCompany ParticipantsJeffrey Stewart - Executive Vice...",
    "url": "https://finnhub.io/api/news?id=907b6c1d4f24f8717a643d603735d8bcd00e8a842c00951a43c227ab66f36454",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733235963,
      "headline": "AbbVie Inc. (ABBV) Citi's 2024 Global Healthcare Conference (Transcript)",
      "id": 131757304,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "AbbVie Inc. (NYSE:ABBV) Citi's 2024 Global Healthcare Conference Call December 3, 2024 10:15 AM ETCompany ParticipantsJeffrey Stewart - Executive Vice...",
      "url": "https://finnhub.io/api/news?id=907b6c1d4f24f8717a643d603735d8bcd00e8a842c00951a43c227ab66f36454"
    }
  },
  {
    "ts": null,
    "headline": "Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock",
    "summary": "AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=2260cf0e556b6892fc4478fad7d345e30a7426e1e587750d87240206b73c2408",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733234418,
      "headline": "Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock",
      "id": 131755177,
      "image": "https://media.zenfs.com/en/zacks.com/0c6f98f4bf655bec3b199bc1a71b8b85",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=2260cf0e556b6892fc4478fad7d345e30a7426e1e587750d87240206b73c2408"
    }
  },
  {
    "ts": null,
    "headline": "J&J Seeks FDA Approval for Tremfya for Psoriasis in Kids",
    "summary": "J&J files for FDA approval of Tremfya for plaque psoriasis and psoriatic arthritis indications in pediatric patients",
    "url": "https://finnhub.io/api/news?id=1caf7d3e3d9b33a4d129c81ae662da556772642b45d708b91de539b460e5229e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733234280,
      "headline": "J&J Seeks FDA Approval for Tremfya for Psoriasis in Kids",
      "id": 131754580,
      "image": "https://media.zenfs.com/en/zacks.com/74bab520128f201c7e6cc3f67385e761",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "J&J files for FDA approval of Tremfya for plaque psoriasis and psoriatic arthritis indications in pediatric patients",
      "url": "https://finnhub.io/api/news?id=1caf7d3e3d9b33a4d129c81ae662da556772642b45d708b91de539b460e5229e"
    }
  },
  {
    "ts": null,
    "headline": "Harding Loevner Global Developed Markets Equity Q3 2024 Report",
    "summary": "Global markets advanced during the third quarter of 2024, with all regions posting gains. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=c425dbcba77923799cf4937ae9d3ebb720fc26b0c088ec8944d5b08b8510b85d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733226300,
      "headline": "Harding Loevner Global Developed Markets Equity Q3 2024 Report",
      "id": 131755093,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1921110478/image_1921110478.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Global markets advanced during the third quarter of 2024, with all regions posting gains. Click here to read the full commentary.",
      "url": "https://finnhub.io/api/news?id=c425dbcba77923799cf4937ae9d3ebb720fc26b0c088ec8944d5b08b8510b85d"
    }
  },
  {
    "ts": null,
    "headline": "SpaceX’s $350 billion private valuation signals an IPO is off the table for now",
    "summary": "SpaceX’s $350 billion private valuation signals an IPO is off the table for now",
    "url": "https://finnhub.io/api/news?id=a8fdd90ae44a1070c1573f2f0f00009071c59623b219b6bea16e0e6b9e6578dc",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733222460,
      "headline": "SpaceX’s $350 billion private valuation signals an IPO is off the table for now",
      "id": 131774735,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "SpaceX’s $350 billion private valuation signals an IPO is off the table for now",
      "url": "https://finnhub.io/api/news?id=a8fdd90ae44a1070c1573f2f0f00009071c59623b219b6bea16e0e6b9e6578dc"
    }
  },
  {
    "ts": null,
    "headline": "3 High-Yield Dividend Growth Stocks to Buy in December and Hold for a Decade or Longer",
    "summary": "It's been a great couple of years for the stock market.  During this bull run, stock prices have bounded forward much further than earnings from their underlying businesses.  As a result, the average dividend payer in the benchmark index offers a paltry 1.2% yield at recent prices.",
    "url": "https://finnhub.io/api/news?id=f7f7d632b419fc0d98b24ffa45e78c2d5f4291d69aecad2ce4f35f7b2f903d50",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733217840,
      "headline": "3 High-Yield Dividend Growth Stocks to Buy in December and Hold for a Decade or Longer",
      "id": 131749258,
      "image": "https://g.foolcdn.com/editorial/images/799277/board-room-chart-getty.jpg",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "It's been a great couple of years for the stock market.  During this bull run, stock prices have bounded forward much further than earnings from their underlying businesses.  As a result, the average dividend payer in the benchmark index offers a paltry 1.2% yield at recent prices.",
      "url": "https://finnhub.io/api/news?id=f7f7d632b419fc0d98b24ffa45e78c2d5f4291d69aecad2ce4f35f7b2f903d50"
    }
  }
]